{"doi":"10.1038/bjc.2011.118","title":"Polygenic susceptibility to prostate and breast cancer: implications for personalised screening","abstract":null,"journal":"British Journal of Cancer","year":2011,"id":641023,"datarank":0.7667981682534817,"base_score":5.111987788356544,"endowment":5.111987788356544,"self_citation_contribution":0.7667981682534817,"citation_network_contribution":0.0,"self_endowment_contribution":0.7667981682534817,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":165,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1666362,"name":"S W Duffy","orcid":null,"position":1,"is_corresponding":false},{"id":1666363,"name":"S Chowdhury","orcid":null,"position":2,"is_corresponding":false},{"id":1666364,"name":"T Dent","orcid":null,"position":3,"is_corresponding":false},{"id":1666365,"name":"H Burton","orcid":null,"position":4,"is_corresponding":false},{"id":1666366,"name":"D E Neal","orcid":null,"position":5,"is_corresponding":false},{"id":1666367,"name":"D F Easton","orcid":null,"position":6,"is_corresponding":false},{"id":1666368,"name":"R Eeles","orcid":null,"position":7,"is_corresponding":false},{"id":1666369,"name":"P Pharoah","orcid":null,"position":8,"is_corresponding":false},{"id":1666361,"name":"N Pashayan","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Polygenic susceptibility to prostate and breast cancer: implications for personalised screening","abstract":"BACKGROUND: We modelled the efficiency of a personalised approach to screening for prostate and breast cancer based on age and polygenic risk-profile compared with the standard approach based on age alone. METHODS: We compared the number of cases potentially detectable by screening in a population undergoing personalised screening with a population undergoing screening based on age alone. Polygenic disease risk was assumed to have a log-normal relative risk distribution predicted for the currently known prostate or breast cancer susceptibility variants (N=31 and N=18, respectively). RESULTS: Compared with screening men based on age alone (aged 55-79: 10-year absolute risk ≥2%), personalised screening of men age 45-79 at the same risk threshold would result in 16% fewer men being eligible for screening at a cost of 3% fewer screen-detectable cases, but with added benefit of detecting additional cases in younger men at high risk. Similarly, compared with screening women based on age alone (aged 47-79: 10-year absolute risk ≥2.5%), personalised screening of women age 35-79 at the same risk threshold would result in 24% fewer women being eligible for screening at a cost of 14% fewer screen-detectable cases. CONCLUSION: Personalised screening approach could improve the efficiency of screening programmes. This has potential implications on informing public health policy on cancer screening.","is_dataset_classified":null,"base_score":5.111987788356544,"endowment":5.111987788356544,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21468051","pmcid":"PMC3093360","openalex_id":"https://openalex.org/W2142722364","authors":[],"funders":[{"funder_name":"Cancer Research UK","grant_id":"A10119","title":null},{"funder_name":"Cancer Research UK","grant_id":"10119","title":null},{"funder_name":"Cancer Research UK","grant_id":"11021","title":null},{"funder_name":"Cancer Research UK","grant_id":"11022","title":null},{"funder_name":"European Commission FP7","grant_id":"FP7_223175","title":null},{"funder_name":"Cancer Research UK","grant_id":"10118","title":null},{"funder_name":"Cancer Research UK","grant_id":"A8358","title":null},{"funder_name":"Medical Research Council","grant_id":"G0900871","title":null},{"funder_name":"Cancer Research UK","grant_id":"10124","title":null},{"funder_name":"European Commission","grant_id":"223175","title":"Collaborative Oncological Gene-environment Study"}],"total_grants":10,"fwci":11.7502,"citation_percentile":0.98962925,"influential_citations":0,"citation_trend":[{"year":2012,"count":16},{"year":2013,"count":22},{"year":2014,"count":13},{"year":2015,"count":18},{"year":2016,"count":12},{"year":2017,"count":12},{"year":2018,"count":7},{"year":2019,"count":11},{"year":2020,"count":11},{"year":2021,"count":11},{"year":2022,"count":12},{"year":2023,"count":8},{"year":2024,"count":5},{"year":2025,"count":5},{"year":2026,"count":1}],"oa_status":"hybrid","license":"cc-by-nc-sa","oa_locations":[{"url":"https://www.nature.com/articles/bjc2011118.pdf","host_type":"journal"},{"url":"https://www.nature.com/articles/bjc2011118.pdf","host_type":"publisher"},{"url":"http://www.nature.com/articles/bjc2011118.pdf","host_type":"publisher"},{"url":"http://www.nature.com/articles/bjc2011118","host_type":"publisher"},{"url":"https://doi.org/10.1038/bjc.2011.118","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21468051","host_type":"repository"},{"url":"http://discovery.ucl.ac.uk/1321868/","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3093360","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093360","host_type":""},{"url":"http://dx.doi.org/10.1038/bjc.2011.118","host_type":""},{"url":"https://dx.doi.org/10.1038/bjc.2011.118","host_type":""}],"fields_of_study":["Prostate Cancer Diagnosis and Treatment","BRCA gene mutations in cancer","Global Cancer Incidence and Screening","03 medical and health sciences","0302 clinical medicine","Adult","Aged","Breast Neoplasms","Female","Genetic Predisposition to Disease","Humans","Male","Mass Screening","Middle Aged","Precision Medicine","Prostatic Neoplasms"],"mesh_terms":["Adult","Aged","Breast Neoplasms","Female","Humans","Male","Mass Screening","Middle Aged","Prostatic Neoplasms","Genetic Predisposition to Disease","Precision Medicine"],"keywords":["Medicine","Prostate cancer screening","Breast cancer screening","Breast cancer","Population","Prostate cancer","Cancer screening","Gynecology","Cancer","Disease","Risk assessment","Internal medicine","Oncology","Mammography","Prostate-specific antigen","Environmental health","Adult","Male","Prostatic Neoplasms","Genetics and Genomics","Breast Neoplasms","Middle Aged","Humans","Mass Screening","Female","Genetic Predisposition to Disease","Precision Medicine","Aged"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"refsnp"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T15:26:43.253586Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}